Liane M. Peterson
Partner
Liane M. Peterson is a first chair trial litigator with extensive experience handling IP litigation matters in U.S. district courts and before the U.S. International Trade Commission (ITC). She is co-chair of the firm’s IP Litigation Practice and a member of the Chemical, Biotechnology & Pharmaceutical Practice. Liane is also a member of the Life Sciences Industry Team as well as the Health Care & Life Sciences and Innovative Technology Sectors.
Liane focuses her practice on complex patent litigation in the pharmaceutical and biotechnology fields, with a particular focus on Hatch-Waxman litigation. She has represented numerous pharmaceutical, biologics, and life sciences companies in litigation at the district court and appellate levels across a wide range of matters involving small molecule drugs, biologics, medical devices, cosmetics, vaccines, and diagnostics. Liane also routinely counsels clients, including startups, and both large pharmaceutical companies and those engaged in early-stage clinical research on a range of pre-litigation matters.
Liane also has significant experience handling Section 337 patent litigation for clients at the ITC and routinely assists clients with a range of IP disputes, including licensing matters, trade secret misappropriation, unfair competition and antitrust claims.
Liane previously worked as a law clerk at the ITC in the Office of Unfair Import Investigations dealing with Section 337 investigations of unfair trade practices involving intellectual property rights. Prior to law school she served as a researcher at The Institute for Genomic Research in Rockville, Md.
Representatieve ervaring
Pharmaceutical and Life Sciences Cases
- Allustra Technologies LLC v. Clarins USA, Inc., 1:22-cv-09948 (S.D.N.Y.)
- Trutek Corp. v. BlueWillow Biologics, Inc., 4:21-cv-10312 (E.D. Mich.)
- Ravgen, Inc. v. Myriad Genetics, Inc., 1:20-cv-01730 (D. Del.)
- Taiho Pharmaceutical Co., Ltd. v. Natco Pharma Ltd., 1:19-cv-02368 (D. Del.)
- Taiho Pharmaceutical Co., Ltd. v. MSN Laboratories Private Ltd., 1:19-cv-02342 (D. Del.)
- Taiho Pharmaceutical Co., Ltd. v. Accord Healthcare Inc., 1:19-cv-02321 (D. Del.)
- Taiho Pharmaceutical Co., Ltd. v. Eugia Pharma Specialties Ltd., 1:19-cv-02309 (D. Del.)
- Noven Pharmaceuticals, Inc. v. Actavis Laboratories UT, Inc., 1:18-cv-00758 (D. Del.)
- Noven Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, 1:18-cv-00699 (D. Del.)
- NuGEN Technologies, Inc. v. Keygene NV, 4:18-cv-00525 (N.D. Cal.)
- Noven Pharmaceuticals, Inc. v. Alvogen Pine Brook LLC, 1:17-cv-01429 (D. Del.)
- Noven Pharmaceuticals, Inc. v. Mylan Technologies Inc., et al., 1:15-cv-00328 (D. Del.)
- Noven Pharmaceuticals, Inc. v. Actavis Laboratories UT, Inc., 1:15-cv-00249 (D. Del.)
- Unimed Pharmaceuticals LLC, et al. v. Sandoz, Inc., 1:15-cv-01120 (D. Del.)
- Unimed Pharmaceuticals LLC, et al. v. Lupin Atlantis Holdings SA, 1:15-cv-00904 (D. Del.)
- AstraZeneca LP, et al. v. HEC Pharm Co., Ltd., 1:15-cv-01041 (D. Del.)
- Actavis Laboratories UT, Inc. v. Par Pharmaceutical, Inc., 1:15-cv-00886 (D. Del.)
- Sebela Pharmaceuticals v. Prinston Pharmaceutical, 2:14-cv-07400 (D.N.J.)
- Sebela Pharmaceuticals v. Actavis Laboratories FL, Inc., 2:14-cv-06414 (D.N.J.)
- Par Pharmaceutical, Inc. v. GlaxoSmithKline LLC and Aptalis Pharma, 1:14-cv-06627 (E.D. Pa.)
- AstraZeneca v. Sagent Pharmaceuticals, Inc. and Glenmark Pharmaceuticals Ltd., 1:14-cv-03547 (D.N.J.)
- Lyne Laboratories, Inc., et al. v. Lupin Ltd., 1:14-cv-10153 (D. Mass.)
- Unimed Pharmaceuticals LLC, et al. v. Perrigo Co., et al., 1:13-cv-00236 (D. Del.)
- Boehringer Ingelheim et al. v. Kremers Urban Pharmaceuticals Inc., 1:13-cv-01580 (D.N.J.)
- Keygene NV v. Floragenex Inc., 3:11-cv-00803 (D. Or.)
- Pfizer Inc. et al. v. Kremers Urban, LLC, et al. (D. Del.)
- Sepracor Inc. et al. v. Pharmaceutical Associates, Inc. (D.N.J.)
- Schering Corp. v. Geopharma, Inc. (D.N.J.)
- Sanofi-Aventis v. Ebewe Pharma (D.N.J.)
ITC Cases
- Certain Residential Premises Security Monitoring and Automation Control Panels, 337-TA-1273
- Certain Fitness Devices, 337-TA-1265
- Certain Wearable Monitoring Devices, 337-TA-1190
- Certain Semiconductor Devices, Semiconductor Device Packages, and Products Containing Same, 337-TA-1010
- Certain Computing or Graphics Systems, Components Thereof, and Vehicles Containing Same, Inv. No. 337-TA-984
- Certain Dental Implants, Inv. No. 337-TA-934
- Certain Integrated Circuits and Products Containing Same, Inv. No. 337-TA-920
- Certain Optoelectronic Devices for Fiber Optic Communications, Inv. No. 337-TA-860
- Certain Motion Sensitive Sound Effects Devices and Image Display Devices and Components and Products Containing Same, Inv. No. 337-TA-773
- Certain Buffer Systems and Components Thereof Used in Container Processing Lines, Inv. No. 337- TA-609
- Certain Lighting Control Devices Including Dimmer Switches and/or Switches and Parts Thereof, Inv. No. 337-TA-599
- Certain Shirts with Pucker-Free Seams and Methods of Producing Same, Inv. No. 337-TA-517
Prijzen en erkenning
- IAM Patent 1000 – The World’s Leading Patent Practitioners (2025)
Affiliaties
- Lid Amerikaanse Orde van Advocaten
- Member, American Intellectual Property Association
- Member, International Trade Commission Trial Lawyers Association
- Lid Federal Circuit Bar Association
Presentaties en publicaties
- “GLP-1 Receptor Agonists: Drug Litigation Overview and Trends,” Health Care Law Today (April 2, 2025)
- “Top Trends to Watch in Pharmaceutical Litigation,” Foley Health Care & Life Sciences Webinar (October 12, 2023)
- “U.S. Patent Litigation, including ITC, Hatch-Waxman and Biosimilar Litigation Proceedings,” presented with Lee & Ko and Korea Pharmaceutical and Bio-Pharma Manufacturers Association (September 26, 2023)
- “Statistics, Trends and Developments in Popular U.S. Patent Litigation Jurisdictions,” Japan Intellectual Property Association (September 27, 2023)
- “Timing Considerations for Section 337 Investigations and IPRs,” Bloomberg Law Professional Perspectives (October 13, 2022)
- “Hot Topics in U.S. Patent Litigation,” Winning in the Unknown – U.S. Intellectual Property Development Seminar Series (January 27, 2021)
- “Assessing the Limitations and Prospects of Obviousness-Type Double Patenting,” ACI Paragraph IV Disputes, New York (August 20-21, 2020)
- “Hatch-Waxman and BPCIA Fundamentals: Examining Follow-On Products and the Rules for Generic Entry,” ACI FDA Boot Camp, New York (March 23-25, 2020) (invited to speak; program cancelled)
- “Hot Topics on Patent Litigation,” 2019 Tokyo IP Conference (October 16, 2019)
- “Assessing Secondary Considerations in Light of Blocking Patents Post-Acorda,” ACI Paragraph IV Disputes, New York (April 29-30, 2019)
- “Latest Patent Litigation and IPR Considerations for Japanese Companies” and “USITC As Successful Venue for Patent Owners,” 2018 Tokyo IP Conference (October 11, 2018)
- “Deciphering the Business Implications of the On-Sale Bar,” ACI Paragraph IV Disputes, New York (April 23-24, 2018)
- “Hatch-Waxman Year-in-Review Panel,” ABA IP Law Section Annual Conference (April 7, 2016)
- “e-Discovery in U.S. Patent Litigation,” Advanced U.S. Patent Litigation Seminar Series, Osaka, Japan and Tokyo, Japan (January 27-28, 2016)
- “Beginning the Litigation: Initial Considerations and Strategies,” U.S. Patent Litigation Seminar Series, Osaka, Japan (May 15, 2014)
- Hatch-Waxman Litigation Seminar, Japan Pharmaceutical Manufacturers Association IP Committee, Tokyo, Japan (May 12, 2014)
- “Expert Discovery, Markman Hearings & Preparing for Trial,” U.S. Patent Litigation Seminar Series, Tokyo, Japan (November 14, 2013)
- “Motions for Summary Judgment, Attorney-Client Privilege and ITC Practice,” U.S. Patent Litigation Seminar Series, Tokyo, Japan (September 12, 2013)
- “Managing E-Discovery in U.S. Patent Litigation,” AIPPI Journal in Japan, Vol. 54, No. 10, 2009
- “Duty of Disclosure Requirements: Best Practice for Handling and Managing Disclosure Requirements,” TACPI D.C. Round Table Seminar (December 18, 2009)
- “Practical Steps to Address E-Discovery: New Battleground in U.S. IP Litigation,” TACPI D.C. Round Table Seminar (August 27, 2009)
- “Strategic Document Management for Corporate IP Practitioners,” presented to NGB and clients in Japan (May 19, 2009)
- “Proper Scope of ITC Remedies After Qualcomm,” IP Law360 (October 22, 2008)
Belangrijkste trends in farmaceutische rechtszaken om in de gaten te houden
Nu de gezondheidszorg en de biowetenschappen zich blijven ontwikkelen, moeten organisaties in het hele land rekening houden met recente trends in farmaceutische rechtszaken. Of het nu gaat om antiroest, intellectueel eigendom, massaslachtoffers of andere geschillen, deze webinar gaat in op de farmaceutische trends die in opkomst zijn in de sector.
GLP-1 geneesmiddelen in beeld: Trends, behoeften en de toekomst
De sectoren Health Care & Life Sciences en Innovative Technology van Foley nodigen u uit voor een webinar over hoe uw organisatie kan navigeren op het kruispunt van GLP-1's en zich kan voorbereiden op dit veranderende landschap.
Foley vertegenwoordigt Verona Pharma bij overname van $10B door Merck
Foley & Lardner LLP trad op als Amerikaans intellectueel eigendomsadviseur voor het in het Verenigd Koninkrijk gevestigde Verona Pharma, een biofarmaceutisch bedrijf dat zich richt op aandoeningen van de luchtwegen, bij de overname van ongeveer $ 10 miljard door Merck & Co. Inc. (Merck).
IAM erkent Foley-advocaten en -rechtsgebieden in editie 2025 van IAM Patent 1000: The World's Leading Patent Practitioners
Zeventien advocaten en vijf rechtsgebieden van Foley & Lardner LLP zijn opgenomen in de 2025-editie van IAM Patent 1000: The World's Leading Patent Practitioners.
GLP-1 receptoragonisten: Overzicht van rechtszaken en trends
De recente toename en populariteit van GLP-1 geneesmiddelen voor gewichtsverlies en obesitas heeft geleid tot een toename in rechtszaken in de VS over deze klasse van geneesmiddelen.
2024 Foley Tokio IP-conferentie
Kom op woensdag 25 september naar de 2024 Foley Tokyo IP Conference - "Navigating the Business of Innovation: Insights on Patent Eligibility, AI, and Other Key IP Developments" - een educatief seminar van een halve dag dat u wegwijs maakt in de laatste juridische ontwikkelingen op het gebied van IE en hun praktische implicaties voor het bedrijfsleven in de Verenigde Staten.